BIIB

Biogen Inc

BIIB, USA

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS; and TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA. It offers RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, and biosimilars. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; and Sage Therapeutics, Inc., as well as collaborations with Fujirebio to identify and develop biomarkers for tau pathology in the brain and Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

https://www.biogen.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
BIIB
stock
BIIB

Rakuten Investment Management Inc. Buys Shares of 198,572 Biogen Inc. $BIIB MarketBeat

Read more →
BIIB
stock
BIIB

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026 MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$191.0345

Analyst Picks

Strong Buy

13

Buy

4

Hold

20

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

14.99

Low 50

High 10

Price to Book Ratio (P/B)

-

Very Low

1.33

Low 1

High 3

Return on Equity (ROE)

-

Very Low

2.56 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

1.60 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

49.96 %

Low 5%

High 15%

Debt to Equity

-

Medium

0.60

Low 1

High 0.3

Investors

* Institutions hold a combined 90.81% of the total shares of Biogen Inc

1.

Vanguard Group Inc

(11.7933%)

since

2025/06/30

2.

PRIMECAP Management Company

(10.778%)

since

2025/06/30

3.

BlackRock Inc

(9.2456%)

since

2025/06/30

4.

Vanguard PRIMECAP Inv

(6.1412%)

since

2025/06/30

5.

State Street Corp

(5.0942%)

since

2025/06/30

6.

Wellington Management Company LLP

(3.2728%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(3.1463%)

since

2025/07/31

8.

Vanguard Health Care Inv

(2.9786%)

since

2025/06/30

9.

Geode Capital Management, LLC

(2.6724%)

since

2025/06/30

10.

Point72 Asset Management, L.P.

(2.6135%)

since

2025/06/30

11.

Vanguard 500 Index Investor

(2.4745%)

since

2025/07/31

12.

Vanguard Mid Cap Index Institutional

(2.2294%)

since

2025/07/31

13.

Invesco QQQ Trust

(2.0599%)

since

2025/08/29

14.

Vanguard Capital Opportunity Inv

(1.639%)

since

2025/06/30

15.

Amvescap Plc.

(1.5825%)

since

2025/06/30

16.

NORGES BANK

(1.5443%)

since

2025/06/30

17.

Morgan Stanley - Brokerage Accounts

(1.3343%)

since

2025/06/30

18.

Fidelity 500 Index

(1.2668%)

since

2025/07/31

19.

iShares Core S&P 500 ETF

(1.2022%)

since

2025/08/31

20.

SPDR® S&P 500® ETF

(1.2017%)

since

2025/08/31

21.

UBS Asset Mgmt Americas Inc

(1.189%)

since

2025/06/30

22.

FMR Inc

(1.1419%)

since

2025/06/30

23.

Northern Trust Corp

(1.0483%)

since

2025/06/30

24.

Legal & General Group PLC

(0.9868%)

since

2025/06/30

25.

T. Rowe Price Investment Management,Inc.

(0.9511%)

since

2025/06/30

26.

Vanguard PRIMECAP Core Inv

(0.937%)

since

2025/06/30

27.

D. E. Shaw & Co LP

(0.9318%)

since

2025/06/30

28.

AQR Capital Management LLC

(0.9309%)

since

2025/06/30

29.

Pacer Advisors, INC.

(0.9003%)

since

2025/06/30

30.

Vanguard Value Index Inv

(0.8858%)

since

2025/07/31

31.

Pacer US Cash Cows 100 ETF

(0.7689%)

since

2025/08/29

32.

Deutsche Bank AG

(0.7661%)

since

2025/06/30

33.

Charles Schwab Investment Management Inc

(0.7337%)

since

2025/06/30

34.

Invesco S&P 500® Equal Weight ETF

(0.7252%)

since

2025/08/29

35.

The Health Care Select Sector SPDR® ETF

(0.6824%)

since

2025/08/31

36.

Vanguard Mid-Cap Value ETF

(0.6288%)

since

2025/07/31

37.

Vanguard Institutional Index I

(0.6035%)

since

2025/07/31

38.

SPDR® S&P Biotech ETF

(0.6013%)

since

2025/08/31

39.

iShares Biotechnology ETF

(0.5951%)

since

2025/08/31

40.

State St S&P 500® Indx SL Cl III

(0.5334%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

1.76

Latest Release

Date

2025-09-30

EPS Actual

4.81

EPS Estimate

3.85

EPS Difference

0.96

Surprise Percent

24.9351%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Strong Deep Value(7.5)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(8.3)
GARP
Fair GARP(3.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4.5)
Net Net
Possible Net-Net(3.5)
Quality
High Quality(7)
Value
Undervalued(8)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.